GlobeNewswire·Nov 4, 2026, 2:01 PM ET

BRIGHT MINDS BIOSCIENCES INVESTIGATION: DRUG Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

Kirby McInerney LLP is investigating potential federal securities law violations & unlawful business practices by Bright Minds Biosciences (NASDAQ: DRUG).
The investigation focuses on Bright Minds' announcement on November 2, 2026, that the FDA placed its Phase 2 BMB-101 clinical trial on a partial clinical hold.
The FDA cited toxicity observed in mice & inadequate pharmacokinetic & juvenile toxicity data to support the proposed pediatric enrollment for Developmental & Epileptic Encephalopathies (DEE).
Bright Minds stated the hold applies only to the U.S. Phase 2 trial, believes the mouse toxicity was incidental & not drug-related, & noted no other species showed similar adverse findings.
On January 6, 2026, the company reported BMB-101 met primary & secondary endpoints & was safe in patients, before the FDA hold news emerged.
Following the FDA announcement, Bright Minds shares declined $28.78 (approximately 52.3%) from $54.98 on October 30, 2026 to close at $26.20 on November 2, 2026.
No lawsuit has been filed yet as the investigation remains ongoing to determine potential claims under federal securities laws.
Investors who purchased Bright Minds securities are encouraged to contact Lauren Molinaro at Kirby McInerney LLP to discuss their rights at no cost.